DIAGNOSTIC MEDICAL SYSTEMS
Diagnostic Medical Systems, trading as DMS Group, is a French société anonyme (SA) governed by a board of directors, registered under SIREN 389 873 142 (SIRET 389 873 142 00050), incorporated on 15 January 1993 and recorded as active on France’s business register maintained by INSEE and the Institut National de la Propriété Industrielle (INPI), with its registration held at the Registre du Commerce et des Sociétés of Nîmes. Its registered office is at 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, in the Gard department of southern France. INSEE classifies the company’s principal registered activity under NAF code 64.20Z, “Activités des sociétés holding” (holding company activities); trading under its DMS Imaging brand, the group designs, develops and manufactures medical imaging systems for digital and conventional radiology, bone densitometry (osteodensitometry), mobile X-ray units, C-arm surgical imaging and mammography, distributed through more than 140 national distributors worldwide. Diagnostic Medical Systems’ shares have traded on Euronext Growth Paris under ISIN FR0012202497 and ticker ALDMS, and the company is eligible for the French PEA-PME savings scheme. In October 2023 the group completed the acquisition of Solutions For Tomorrow AB, a Swedish manufacturer of motorised mobile X-ray systems. For the financial year ended 31 December 2025, DMS Group reported consolidated revenue of 50.0 million euros, organic growth of approximately 8.5% over 2024 and a return to net profitability, up from consolidated revenue of approximately 35 million euros in 2022, with more than 80% of 2025 revenue generated internationally. In August 2025 the company completed a capital increase of approximately 6.9 million euros reserved to InnoLux Corporation, InnoCare Optoelectronics Corporation, Bpifrance Participations and NextStage AM alongside existing investor Verso Capital. As of September 2025 the group employed approximately 150 people at its Gallargues-le-Montueux site. Registration as active on the French business register does not by itself confirm current trading activity.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Shareholders of Diagnostic Medical Systems
Diagnostic Medical Systems (DMS Group) is listed on Euronext Growth Paris, a market segment where public disclosure generally covers only shareholders above defined notification thresholds rather than a complete share register. Following a capital increase of approximately 6.9 million euros completed on 15 August 2025 and reserved to a group of institutional investors, the company’s disclosure of the resulting shareholding structure reported: Verso Capital, a pre-existing investor whose stake increased through the operation, 20.4% of share capital (20.1% of voting rights); NextStage AM, 9.1% of capital (9.0% of voting rights); Bpifrance Participations, 6.3% of capital (6.2% of voting rights); InnoLux Corporation, 3.2% of capital (3.1% of voting rights); and InnoCare Optoelectronics Corporation, 3.2% of capital (3.1% of voting rights). Together these five investors held just over 40% of share capital immediately after the August 2025 operation, with the remainder held in free float and by other shareholders not individually named in the disclosure reviewed. A later regulatory notice on the composition of share capital and voting rights, dated 31 August 2026, reported 26,686,791 shares in issue, 30,804,939 theoretical voting rights and 30,006,734 exercisable voting rights, but did not restate individual shareholding percentages.
Ultimate beneficial ownership
No authoritative source reviewed identifies an individual as a beneficial owner of Diagnostic Medical Systems, and no complete, dated ownership chain is available to calculate an effective indirect percentage for any of the corporate shareholders listed above. No ultimate beneficial owner is therefore reported.
Data availability
Shareholder disclosure for Diagnostic Medical Systems is classified as Major shareholders only: holdings above the applicable notification thresholds are published through company announcements and regulatory capital/voting-rights notices, but a complete shareholder register is not publicly available for this Euronext Growth-listed company.
Sources
- DMS Group / Diagnostic Medical Systems, regulatory press release on the reserved capital increase, webdisclosure.com, 15 August 2025
- DMS Group, “Information relative au nombre total de droits de vote et d’actions composant le capital au 31 août 2026”, webdisclosure.com, published 3 September 2026
- Autorité des Marchés Financiers (AMF), major-shareholding disclosure regime for Euronext Growth issuers
Officers
19
Directors and officers of Diagnostic Medical Systems
Diagnostic Medical Systems (DMS Group) is a société anonyme governed by a board of directors (conseil d’administration). According to France’s INSEE business register and the company’s official corporate-governance disclosures, the board comprises Samuel Sancerni (Chairman of the board), Marie-Laurence Borie, Julien Delpech and Jean-François Gendron (independent directors), and Bpifrance Investissement, represented on the board by Vladislav Tcaci. Two non-voting censors also sit on the board: Tim Yang, representing InnoLux Corporation and InnoCare Optoelectronics Corporation, and Marko Järvinen, representing Verso Capital. Julien Delpech was elected to the board as an independent director at the ordinary general meeting of 16 June 2025. The company’s statutory auditors are Deloitte & Associés, whose mandate was renewed on 17 June 2024 and runs to 31 December 2029, and Mazars, whose mandate was renewed on 18 July 2022 and runs to 31 December 2027, with BEAS acting as alternate auditor. Appointment dates, occupations, nationality and country of residence are not disclosed in the sources reviewed for most board members, and in line with this profile’s sourcing rules these are reported as not disclosed rather than inferred from names or affiliations.
Recent officer changes
- Julien Delpech was appointed as an independent director at the ordinary general meeting of 16 June 2025 (source: company governance disclosure).
Data availability
Officer information for Diagnostic Medical Systems is classified as Partial: current board composition, including independent directors and investor-nominated administrators and censors, is confirmed through the INSEE business register and the company’s official governance page, but full appointment histories, occupations, nationality and country of residence are not comprehensively disclosed in the sources reviewed.
Sources
- INSEE / Recherche d’entreprises (data.gouv.fr), official business register extract for SIREN 389873142, retrieved 18 September 2026
- DMS Group, Gouvernement d’entreprise, dms-imaging.com/fr/gouvernement-dentreprise/, retrieved 18 September 2026
- DMS Group company disclosure on board composition following the ordinary general meeting of 16 June 2025
Registry feed — rows exactly as filed with INPI (Institut National de la Propriété Industrielle), including entries the profile above does not cover.
Group Structure
Group structure of Diagnostic Medical Systems
Diagnostic Medical Systems SA (DMS Group) is the publicly listed parent company of its group; no immediate or ultimate parent company above Diagnostic Medical Systems SA was identified in the sources reviewed. “DMS Imaging” is a trade name and brand under which Diagnostic Medical Systems SA operates its website and markets its radiology and bone-densitometry products, and is not a separately incorporated entity distinct from the listed company, per the company’s own legal notice. INSEE records the company’s principal registered activity as holding-company activities (NAF code 64.20Z, “Activités des sociétés holding”). A verified direct subsidiary is Solutions For Tomorrow AB, a Swedish manufacturer of motorised mobile X-ray systems based in Väckelsång, Sweden, acquired by the group through a share-swap transaction that completed on 3 October 2023. No registration number or ownership percentage for Solutions For Tomorrow AB was disclosed in the sources reviewed. Older company and press disclosures from around 2018-2022 referred to a separately-listed “DMS Imaging” governance structure and a biotechnology-related “DMS Biotech” activity; no source reviewed for this profile dated 2023 or later confirms that either arrangement remains current, so neither is reported as a present-day group relationship.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| Solutions For Tomorrow AB | Sweden | Not disclosed | Direct subsidiary | Ownership percentage not disclosed | Active | 3 October 2023 (acquisition completion) |
Recent structural changes
- Completion of the acquisition of Solutions For Tomorrow AB (Sweden), a manufacturer of motorised mobile X-ray systems, on 3 October 2023, carried out through a share-swap issuance.
Data availability
Corporate-linkage information for Diagnostic Medical Systems is classified as Partial: the existence of the Solutions For Tomorrow AB subsidiary is confirmed through company announcements, but its registration number and precise ownership percentage were not disclosed in the sources reviewed, and no consolidation-scope list of all group entities was located.
Sources
- DMS Group, “Finalisation of the acquisition of Solutions For Tomorrow (SFT)”, actusnews.com, 3 October 2023
- Verso Capital, portfolio news on the Solutions For Tomorrow acquisition, versocapital.com, retrieved 18 September 2026
- DMS Imaging, legal notice (mentions légales), dms-imaging.com/fr/mentions-legales/, retrieved 18 September 2026
- INSEE / Recherche d’entreprises (data.gouv.fr), official business register extract for SIREN 389873142 (NAF code 64.20Z), retrieved 18 September 2026
Registry feed — rows exactly as filed with INPI (Institut National de la Propriété Industrielle), including entries the profile above does not cover.
DIAGNOSTIC MEDICAL SYSTEMS
France
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What is the legal name and legal form of the company registered under SIREN 389873142?
The company is Diagnostic Medical Systems, trading as DMS Group, a French société anonyme (SA) governed by a board of directors.
What is Diagnostic Medical Systems' SIREN and SIRET registration number?
Its SIREN is 389 873 142 and its SIRET is 389 873 142 00050.
When was Diagnostic Medical Systems incorporated?
It was incorporated on 15 January 1993.
Where is Diagnostic Medical Systems registered and headquartered?
Its registered office is at 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France, and it is registered with the Registre du Commerce et des Sociétés of Nîmes.
In which country is Diagnostic Medical Systems incorporated?
France.
What is Diagnostic Medical Systems' current registration status?
France's INSEE business register records the company as active (état administratif A) as of the most recent retrieval.
Is Diagnostic Medical Systems a publicly listed company?
Yes. Its shares trade on Euronext Growth Paris under ISIN FR0012202497 and ticker ALDMS.
What does DMS Group / Diagnostic Medical Systems do?
Trading under the DMS Imaging brand, the group designs, develops and manufactures medical imaging systems for digital and conventional radiology, bone densitometry, mobile X-ray and C-arm surgical imaging, distributed through more than 140 national distributors.
What is Diagnostic Medical Systems' NAF/APE activity code?
INSEE classifies its principal registered activity under NAF code 64.20Z, Activités des sociétés holding (holding company activities).
Who chairs Diagnostic Medical Systems' board of directors?
Samuel Sancerni, per the company's official governance disclosures.
Does Diagnostic Medical Systems have subsidiaries?
A verified direct subsidiary is Solutions For Tomorrow AB, a Swedish mobile X-ray manufacturer acquired in October 2023; no full list of consolidated subsidiaries was disclosed in the sources reviewed.
What was Diagnostic Medical Systems' revenue in its most recently reported financial year?
DMS Group reported consolidated revenue of 50.0 million euros for the year ended 31 December 2025, organic growth of approximately 8.5% over 2024.
Are Diagnostic Medical Systems' shareholders publicly disclosed?
Only major shareholders above applicable notification thresholds are disclosed, as is typical for Euronext Growth Paris-listed companies; a complete share register is not publicly available.
Does Diagnostic Medical Systems have a company website?
Yes, its official website is https://www.dms-imaging.com/.
How is Diagnostic Medical Systems' company data kept up to date on Zavia.ai?
Zavia.ai periodically reviews official company-registry, securities-market and regulatory-filing sources to refresh this Diagnostic Medical Systems profile, and this company's record can also be accessed through the Zavia.ai company data API.